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Impact of Prasugrel Reload Dosing Regimens on
High On-Treatment Platelet Reactivity Rates in
Patients on Maintenance Prasugrel Therapy
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Naveen Seecheran, MD,* Bhaloo Desai, PHD,* Fabiana Rollini, MD,*
Luis A. Guzman, MD,* Theodore A. Bass, MD,* Dominick J. Angiolillo, MD, PHD*
Jacksonville, Florida; and Barcelona, SpainIn acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI),
prasugrel is associated with a greater reduction in atherothrombotic events, albeit at the expense of
increased bleeding, compared with clopidogrel (1). However, despite its greater antiplatelet potency
compared with clopidogrel, recent investigations have shown that prasugrel-treated patients may still have
high on-treatment platelet reactivity (HPR) and remain at risk for ischemic recurrences (2). Of note, these
pharmacodynamic (PD) assessments were limited to a single assay and HPR cutoff value, potentially
overestimating the true prevalence of HPR, which would be more comprehensively defined by using
multiple assays and other recommended cutoff values (2,3). In addition, PD assessments were performed
in the peri-PCI period, during which spuriously higher rates of HPR are measured and which decrease over
time once patients are in their steady-state maintenance phase of therapy (3,4). This may explain why results
of PD testing performed remote from PCI have greater prognostic significance than those obtained in the
peri-PCI period (4). To date, there is limited information on the PD effects of prasugrel and rates of HPR using
multiple PD assays and cutoff values while patients are in their steady-state phase of treatment.
This is a post-hoc analysis of a prospective, randomized, PD study recently reported in JACC (5). Details
of the inclusion and exclusion criteria and study design for the main trial have been published previously
(5). In brief, patients in a steady-state phase of prasugrel maintenance therapy (10 mg daily) for at least 14
days after an ACS undergoing PCI were studied. Patients were randomized (1:1:1 fashion) to receive 10,
30, or 60 mg of prasugrel, and PD testing was conducted at 3 time points: baseline, and 1 and 4 h following
dosing. Baseline PD assessments were representative of trough levels of platelet reactivity (last maintenance
dose taken 18 to 24 h before blood sampling). Platelet function assays included flow cytometric analysis of
the phosphorylation status of the vasodilator-stimulated phosphoprotein (VASP), VerifyNow P2Y12 assay
(Accumetrics, San Diego, California), and light transmission aggregometry (LTA) using 5 and 20 mol/l
adenosine diphosphate (ADP) as stimuli. In the present analysis, established cutoff points that have been
associated with adverse ischemic events were used to define HPR: platelet reactivity index (PRI)50% for
VASP assay; P2Y12 reaction units (PRU) 230 for the VerifyNow P2Y12 assay; and 46% and 59%
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183maximal platelet aggregation (MPA) for LTA using 5 and
20 mol/l ADP, respectively (3). Categorical variables were
xpressed as frequencies and percentages. Intragroup com-
arisons of HPR were performed with the McNemar test or
inomial exact. Chi-square test or Fisher exact test (accord-
ng to application conditions) were used to compare the
ercentage of patients with HPR among treatment groups
intergroup comparisons). A p value 0.05 was considered
tatistically significant for all comparisons.
A total of 64 patients who completed all time periods
ere studied: 10 mg (n  22), 30 mg (n  21), and 60 mg
n  21). In the overall study population, the percentage of
PR patients at baseline ranged from 6.3% to 12.5%,
epending on the assay used (VASP: 12.5%, VerifyNow
2Y12: 7.8%, LTA ADP 5 M: 9.4%, LTA ADP 20 M:
6.3%). Although nonstatistically significant p values were
obtained for all intra- or intergroup comparisons, the 30-mg
and 60-mg dosing regimens achieved numerically lower
HPR rates compared with the 10-mg dosing at 1 and 4 h
using all assays (Table 1). In particular, following a 10-mg
dose, rates of HPR remained either unchanged or reduced,
depending on the assay used, ranging from 0% to 9.1%
(Table 1). Following a 30-mg or 60-mg dose, rates of HPR
decreased at 1 and 4 h. However, HPR rates were always
null only with a 60-mg dose.
The findings of the present investigation conducted in
patients who suffered an ACS and underwent PCI demon-
strate that: 1) trough levels of platelet reactivity (18 to 24 h
after last maintenance dose) in patients in their steady-state
phase of prasugrel therapy are overall low, ranging from
6.3% to 12.5%, depending on the assay used; 2) 4 h
following a 10-mg dose (approximating peak platelet reac-
tivity levels), HPR rates were overall reduced, ranging from
0% to 9.1% depending on the assay used; and 3) following
a 30-mg or 60-mg dose, HPR rates were reduced with all
Table 1. HPR Rates Measured With Different Platelet Function Assays in P
Escalating Prasugrel Dosing Regimens
HPR Definition Time Point Overall (N  64
VASP 50% PRI Baseline 8 (12.5%)
1 h 2 (3.1%)
4 h 2 (3.1%)
VN-P2Y12 230 PRU Baseline 5 (7.8%)
1 h 3 (4.7%)
4 h 1 (1.6%)
LTA (ADP 5 M) 46% MPA Baseline 6 (9.4%)
1 h 2 (3.1%)
4 h 2 (3.1%)
LTA (ADP 20 M) 59% MPA Baseline 4 (6.3%)
1 h 1 (1.6%)
4 h 1 (1.6%)
ADP  adenosine diphosphate; HPR  high on-treatment platelet reactivity; LTA  light transmitreaction units; VASP vasodilator-stimulated phosphoprotein assay; VN-P2Y12 VerifyNow P2Y12 assay.assays with only 1 patient per-
sisting with HPR after a 30-mg
dose and no patients with HPR
after a 60-mg dose. Several take-
home messages derive from
these observations. First, similar
to the more established experience
with clopidogrel, in prasugrel-
treated patients, rates of HPR may
be subject to variability according to
the PD assay used, with VASP-
PRI showing the highest rates (3).
However, HPR rates defined by
VASP-PRI assessed in our study
population in their steady-state
phase of maintenance prasugrel
therapy were markedly lower
(12.5% for trough levels and 9.1%
for peak levels after maintenance
dose) than those previously reported
from PD assessments following a
60-mg loading dose administration conducted in the peri-PCI
period (25% HPR rate) (2). These observations suggest that not
only the assay chosen, but also the timing of PD assessments
has an important impact on more accurately defining HPR
rates. This is in line with findings from PD studies with
clopidogrel showing that response rates performed remote
from the peri-PCI period, once patients are in their steady-
state phase of treatment, not only improve, but also have
better prognostic value (4). Further, our study results may
also have practical implications for prasugrel-treated pa-
tients requiring subsequent revascularization (e.g., due to
chronic progression of coronary atherosclerotic disease pro-
cesses or staged PCI). We acknowledge the inherent limi-
tations of this investigation as being a post hoc analysis of a
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
HPR  high on-treatment
platelet reactivity
LTA  light transmission
aggregometry
MPA  maximal platelet
aggregation
PCI  percutaneous
coronary interventions
PD  pharmacodynamic
PRI  platelet reactivity
index
PRU  P2Y12 reaction units
VASP  vasodilator-
stimulated phosphoprotein
ts on Maintenance Prasugrel Therapy Before and After
10 mg (n  22) 30 mg (n  21) 60 mg (n  21)
5 (22.7%) 2 (10.5%) 1 (4.8%)
2 (9.1%) 0 (0%) 0 (0%)
2 (9.1%) 0 (0%) 0 (0%)
2 (9.1%) 2 (9.5%) 1 (4.8%)
2 (9.1%) 1 (4.8%) 0 (0%)
1 (4.5%) 0 (0%) 0 (0%)
2 (9.1%) 2 (9.5%) 2 (9.5%)
1 (4.5%) 1 (4.8%) 0 (0%)
1 (4.5%) 1 (4.8%) 0 (0%)
1 (4.5%) 2 (9.5%) 1 (4.8%)
1 (4.5%) 0 (0%) 0 (0%)
0 (0%) 1 (4.8%) 0 (0%)
ggregometry; MPA  maximal platelet aggregation; PRI  platelet reactivity index; PRU  P2Y12atien
)
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184PD study. Indeed, a prospective randomized study powered
to detect differences in outcomes is warranted to support the
clinical implications of our analysis. The findings of the
present investigation show that an additional loading dose
of prasugrel is useful to overcome HPR; in particular, there
were no cases of HPR following a 60-mg loading dose.
Therefore, although our study does not provide any insights on
the safety or efficacy of a 60-mg loading dose strategy in
patients already on chronic prasugrel, it is well established that
HPR rates are associated with increased peri-PCI complica-
tions. Therefore, our study offers information on the PD effects
of reloading patients on chronic prasugrel therapy and strate-
gies to minimize HPR rates.
Reprint requests and correspondence: Dr. Dominick J. Angio-
lillo, University of Florida, College of Medicine–Jacksonville, 655
West 8th Street, Jacksonville, Florida 32209. E-mail:
dominick.angiolillo@jax.ufl.edu.REFERENCES
1. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl J Med
2007;357:2001–15.
2. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet
reactivity after prasugrel loading dose and cardiovascular events after
percutaneous coronary intervention in acute coronary syndromes. J Am
Coll Cardiol 2011;58:467–73.
3. Bonello L, Tantry US, Marcucci R, et al. Consensus and future
directions on the definition of high on-treatment platelet reactivity to
adenosine diphosphate. J Am Coll Cardiol 2010;56:919–33.
4. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of
on-clopidogrel platelet reactivity over time in patients treated with
percutaneous coronary intervention relationship with gene polymor-
phisms and clinical outcome. J Am Coll Cardiol 2011;57:2474–83.
5. Tello-Montoliu A, Tomasello SD, Ferreiro JL, et al. Pharmacodynamic
effects of prasugrel dosing regimens in patients on maintenance prasugrel
therapy: results of a prospective randomized study. J Am Coll Cardiol
2012;59:1681–7.
Key Words: antiplatelet drugs  nonresponsiveness 
prasugrel.
